176694-36-3

Usage

Uses

Used in Organic Synthesis:
Methyl 4-fluoro-3-(trifluoromethyl)benzoate is used as a building block in organic synthesis for its unique structure and properties, enabling the creation of a variety of complex organic compounds.
Used in Pharmaceutical Research:
In pharmaceutical research, Methyl 4-fluoro-3-(trifluoromethyl)benzoate is utilized as a key intermediate, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Production:
Methyl 4-fluoro-3-(trifluoromethyl)benzoate is used as a component in the production of agrochemicals, where its specific chemical properties can enhance the effectiveness of these products.
Used in Pharmaceutical Production:
Methyl 4-fluoro-3-(trifluoroMethyl)benzoate is also used in the production of pharmaceuticals, where its unique characteristics can contribute to the development of novel medications.
Used in Materials Science:
Methyl 4-fluoro-3-(trifluoromethyl)benzoate is employed in materials science for its potential to improve or create new materials with specific properties.
Used as a Reagent in Chemical Reactions:
Due to its precise structure and properties, Methyl 4-fluoro-3-(trifluoromethyl)benzoate is often used as a reagent in various chemical reactions, facilitating specific transformations and syntheses.

InChI:InChI=1/C9H6F4O2/c1-15-8(14)5-2-3-7(10)6(4-5)9(11,12)13/h2-4H,1H3

Upstream product

• 67-56-1 methanol 
• 67515-55-3 4-fluoro-3-(trifluoromethyl)benzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 1005408-85-4 methyl 4-(octylthio)-3-(trifluoromethyl)benzoate 
• 261505-95-7 methyl 4-(4-benzyl-1-piperazinyl)-3-trifluoromethyl-benzoate 
• 176751-69-2 methyl 4-(3-pyridyloxy)-3-trifluoromethylbenzoate 
• 176694-35-2 N-tert-butoxycarbonyl-4-[(4-methoxycarbonyl-2-methylsulfonyl)phenoxy]-phenylalanine benzyl ester 
• 1195951-84-8 C₂₅H₁₇Cl₂F₃N₂O₄ 
• 1192847-36-1 C₁₁H₆Br₂F₃N₃O₂ 
• 1211776-37-2 4-(acridin-9-ylamino)-3-trifluoromethyl-benzoic acid methyl ester 
• 1055361-75-5 4-(4-formyl-2-methoxyphenoxy)-3-trifluoromethylbenzoic acid methyl ester 
• 1195951-86-0 C₃₁H₂₈Cl₂F₃N₃O₅ 
• 1195951-87-1 C₂₇H₂₀Cl₂F₃N₃O₅ 
• 1195951-85-9 C₂₄H₁₅Cl₂F₃N₂O₄ 
• 1393368-57-4 1H-pyrrole-2-carboxylic acid [1-(4-guanidinocarbonyl-2-trifluoromethyl-phenyl)piperidin-3-yl]amide trifluoroacetic acid 

Relevant academic research and scientific papers

FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS

Provided are fused tricyclic amide compounds, pharmaceutical compositions comprising at least one such fused tricyclic compound, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain tricyclic amide compounds that can be useful for inhibiting multiple (specifically BRAF and/or EGFR-T790M) kinases and for treating disorders mediated thereby.

2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF

[Object] Provided is a compound which has an excellent S1P1 agonist action, and is useful particularly as an active ingredient for an agent for preventing and/or treating a disease induced by undesirable lymphocyte infiltration or a disease ind

GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE

The present invention relates to compounds of general formula (I), wherein ring A, ring B, R1, R2, R3, Z, and L1 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.

SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS

The present invention relates to compounds of Formula (I): methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

CHEMICAL COMPOUNDS

The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, a

SUBSTITUTED BENZOYLGUANIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT OR DIAGNOSTIC AND MEDICAMENT COMPRISING THE SAME

The present invention relates to substituted benzoylguanidines of the formula I: in which R1 to R8 and X and Y are as described in the specification, and their pharmaceutically acceptable salts are substituted acylguanidines as inhibitors of the cell

SUBSTITUTED BENZOYLGUANIDINES METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT OR DIAGNOSTIC AND MEDICAMENT COMPRISING THE SAME

The invention relates to substituted benzoylguanidines of formula (I), where R1 to R8, X and Y have the meanings given in the claims and the pharmaceutically-acceptable salts thereof which are substituted acylguanidines and inhibit cellular Sodium/Proton antiporter (Na+/H+-Exchanger, NHE). Compounds of formula (I) and the pharmaceutically-acceptable salts thereof are suitable for the prevention and treatment of disease caused by activation of or by an activated NHE as a result of the NHE-inhibitory properties thereof and also of secondary diseases caused by damage brought about by the NHE.

Substituted sulfonimidamides, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them

Substituted sulfonimidamides, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them Sulfonimidamides of the formula I STR1 in which at least one of the three substituents R(1), R(2) and R(3) is a benzoylg